Sameek Roychowdhury MD, PhD

Sameek Roychowdhury MD, PhD
Asst ProfessorCollege of Medicineroychowdhury.1@osu.eduwebsite
508 Graves Hall 460 W 12th Avenue Columbus Ohio 43210
Phone:614-685-5842Fax: 614-292-6356
  • Experimental Therapeutics

Research Description

Dr. Roychowdhury’s research interests involve translating next generation DNA sequencing strategies for the development of genomics-driven clinical trials. He joined the Division of Medical Oncology in September 2012. His clinical study entitled “Personalized Oncology Through High-Throughout Sequencing” evaluates individual patients with advanced cancer considering clinical trials, and seeks to identify “driving” mutations that match novel molecularly targeted therapies in development. The overarching goal is to identify putative predictive genomic biomarkers for targeted therapies and understand primary and secondary resistance mechanisms for these therapies. His clinical practice in medical oncology includes patients with advanced cancer including prostate, colorectal, soft tissue sarcoma, and rare cancer subtypes.

Current Publications

  • Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AMActivating ESR1 mutations in hormone-resistant metastatic breast cancer.Nat Genet 45 1446-51 12/1/2013
  • Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AMIdentification of targetable FGFR gene fusions in diverse cancers.Cancer Discov 3(6) 636-47 6/1/2013
  • Roychowdhury S, Chinnaiyan AMAdvancing precision medicine for prostate cancer through genomics.J Clin Oncol 31(15) 1866-73 5/20/2013
  • Simon R, Roychowdhury SImplementing personalized cancer genomics in clinical trials.Nat Rev Drug Discov 12(5) 358-69 5/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu